Ticker

No recent analyst price targets found for IGC.

Latest News for IGC

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it…

Accesswire • Jul 9, 2026
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Chief Executive…

Accesswire • Jul 7, 2026
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS Newswire / June 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled…

Accesswire • Jun 23, 2026
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's…

Accesswire • Jun 11, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the…

Accesswire • Jun 9, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for IGC.

No House trades found for IGC.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top